End of an era as beloved Offaly postmistress retires
Postmistress Maura Naughton behind the counter where she provided a top class service for 29 years
Reporter: );
);
IT was the end of an era for Clara as their much-beloved postmistress Maura Naughton retired recently.
Friends paid this tribute to Maura who ran the facility for the past 29 years. It is with sadness that Clara says goodbye to our beloved postmistress Maura Naughton. Everyone who entered the post office knew Maura to be a lady, always helpful and discreet. The perfect attribute for a person in such a prestigious position, where trustworthiness is key.
Valley News - Forum, April 22: NH underfunds prevention, treatment of mental illness
vnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from vnews.com Daily Mail and Mail on Sunday newspapers.
A Life: Maura Keyes Naughton; ‘She continued to learn and to teach’
Maura Naughton, who teaches Gaelic at Lebanon College, at her home in Wilder, Vt., on Feb. 6, 2014. (Valley News - Sarah Priestap) Copyright Valley News. May not be reprinted or used online without permission. Send requests to permission@vnews.com.
Maura Naughton around age 18 with her mother Ellen Keyes,, a beloved teacher in Limerick, Ireland. (Family photograph)
Maura Naughton, of Wilder, Vt., pours tea while teaching Patrick Maher, of Reading, Vt., how to say tea in Gaelic during Naughton s class at Lebanon College in Lebanon, N.H., on Jan. 22, 2014. Maher was born in Ireland, visits Ireland yearly, and wishes to learn Gaelic to learn more about his heritage and the place he visits often. (Valley News - Sarah Priestap) Copyright Valley News. May not be reprinted or used online without permission. Send requests to permission@vnews.com.
E-Mail
Boston, Mass. Renal cell carcinoma (RCC) is the most common form of cancer of the kidney. In 2018, there were an estimated 403,000 new cases of RCC and 175,000 deaths due to kidney cancer worldwide. Currently, the 5-year survival rate for patients with metastatic RCC is only about 12 percent. Current treatments include inhibitors of the VEGF and PD-1 pathways. However, resistance to therapy occurs in most patients and new combination treatments are still needed to enhance the efficacy of these current approaches.
Now, investigators have demonstrated that ACE2 expression is a good prognostic factor in RCC, that loss of ACE2 mediates resistance to classical treatments, and that in preclinical models, treatment with a drug that is downstream of ACE2 can improve tumor responses in RCC and significantly prolong survival. The team, led by Beth Israel Deaconess Medical Center s (BIDMC) Rupal Bhatt, MD, PhD, and University College Cork, Ireland s Thomas Walther, PhD, published